Foundation Studies

The RTOG Foundation Study Pages are accessible to participating institutions via a username and password. For further information regarding participation on a specific trial send an email to and include the name of the trial in your email.

RTOG Foundation Study 3507

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

RTOG Foundation Study 3515

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4)

ACR 3518

Phase I Safety Assessment of Hypofractionated Postoperative Radiotherapy (H-PORT) for Intermediate-Risk Head and Neck Cancer

CHS-007-01/ RTOG Foundation Study 3521

TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naive Participants.

RTOG Foundation Study 3501

TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (TYKERB®) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation

RTOG Foundation Study 3502

POSTILV: A Randomized Phase II Trial In Patients With Operable Stage I Non-Small Cell Lung Cancer: Radical Resection Versus Ablative Stereotactic Radiotherapy

RTOG Foundation Study 3503

Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

RTOG Foundation Study 3504

Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemoradiotherapy in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma

RTOG Foundation Study 3505

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

RTOG Foundation Study 3506

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs. Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

RTOG Foundation Study 3508/AbbVie 414_M13-813

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

RTOG Foundation Studies 3509 and 3510/RADCOMP

Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium

Frequently Asked Questions

All studies listed on the RTOG Foundation Studies webpage are actively accruing RTOG Foundation studies.

The RTOG Foundation had its origins in 1997 when the RTOG Fund under the auspicious of the American College of Radiology, the grant holder for the Radiation Therapy Oncology Group (RTOG), was created for the purpose of receiving and allocating corporate and private donations to allow the Group to sustain and expand important activities critical to its research mission. In August 2013, the RTOG Foundation incorporated as a nonprofit foundation in the Commonwealth of Pennsylvania and in July 2014, RTOG Foundation, Inc., received its 501(c)3 nonprofit status from the Internal Revenue Service

The RTOG Foundation continues the NCI-funded research of the Radiation Therapy Oncology Group through its membership in NRG Oncology. In addition it has developed a portfolio of industry-funded research partnerships that seek to further our understanding of effective therapies to improve the survival and quality of life of patients with cancer.

RTOG Foundation has maintained its relationships with the core members from the legacy Radiation Therapy Oncology Group and is able to access new members through its membership in NRG Oncology. Today, RTOG is a dynamic multidisciplinary research group with vigorous participation by physicians and other investigators at many of NCI’s designated cancer centers, major community centers, and many of the major academic and regional centers of Canada. RTOG also has a strong international presence with access to sites on four continents. This participation includes leadership from medical oncologists, surgical oncologists, pathologists, and laboratory scientists, as well radiation oncologists.

Access is granted per study to participating sites (those who have an executed Master Service Purchased Agreement and Study-Specific Statement of Work) or sites interested in participating with an executed Confidentiality and Non-Disclosure Agreement on file. If you are interested in learning more about a specific trial, please send an email to and include the name of the trial in your email.

The RTOG Foundation Manual of Operations provides general information about participation in RTOG Foundation studies. Study-specific manuals explain the oversight, reporting and monitoring/auditing requirements for each trial. The study-specific manuals are available to the staff at sites participating in that trial.

RTOG Foundation trials are conducted outside of the NRG Oncology NCI portfolio and infrastructure. For example, regulatory collection occurs at RTOG Headquarters and not through the CTSU.

At the present time, RTOG Foundation studies are not membership based. There are no minimum accrual requirements. Data submission quality and timeliness is monitored and sites are regularly audited.

Since RTOG Foundation trials are conducted outside of the NRG Oncology NCI portfolio and infrastructure, your site will not receive NRG credit for participation on RTOG Foundation studies.

Yes, when a trial is open to sites in Canada, the RTOG Foundation will apply for the CTA with Health Canada for trials involving drugs.

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email or call 1-215-574-3173.

See our clinical trials